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Background: This phase III open-label trial investigated the efﬁcacy of nilotinib in patients with advanced
gastrointestinal stromal tumors following prior imatinib and sunitinib failure.
Patients and methods: Patients were randomized 2 : 1 to nilotinib 400 mg b.i.d. or best supportive care (BSC; BSC
without tyrosine kinase inhibitor, BSC + imatinib, or BSC + sunitinib). Primary efﬁcacy end point was progression-free
survival (PFS) based on blinded central radiology review (CRR). Patients progressing on BSC could cross over to
nilotinib.
Results: Two hundred and forty-eight patients enrolled. Median PFS was similar between arms (nilotinib 109 days,
BSC 111 days; P = 0.56). Local investigator-based intent-to-treat (ITT) analysis showed a signiﬁcantly longer median
PFS with nilotinib (119 versus 70 days; P = 0.0007). A trend in longer median overall survival (OS) was noted with
nilotinib (332 versus 280 days; P = 0.29). Post hoc subset analyses in patients with progression and only one prior
regimen each of imatinib and sunitinib revealed a signiﬁcant difference in median OS of >4 months in favor of nilotinib
(405 versus 280 days; P = 0.02). Nilotinib was well tolerated.
Conclusion: In the ITT analysis, no signiﬁcant difference in PFS was observed between treatment arms based on
CRR. In the post hoc subset analyses, nilotinib provided signiﬁcantly longer median OS.
Key words: gastrointestinal stromal tumors, GIST, imatinib, nilotinib, sunitinib, tyrosine kinase inhibitor
introduction
Historically, the prognosis for patients with unresectable or
metastatic gastrointestinal stromal tumors (GIST) has been
poor [1]. The introduction of the tyrosine kinase inhibitor
(TKI) imatinib mesylate (Gleevec®/Glivec®, Novartis Pharma
AG, Basel, Switzerland) revolutionized the management of
GIST, providing a median overall survival (OS) of 57 months
versus the 19 expected in the preimatinib era [1–6].
Despite these improvements, most patients eventually
progress on imatinib, and a small percentage of patients are
intolerant of the drug [6–9]. Sunitinib malate (Sutent®, Pﬁzer
Pharmaceuticals, New York), a multiple receptor TKI, is the
only approved second-line treatment option for GIST patients
intolerant of or progressing on imatinib [10].
To date, there are no approved therapies available for
patients with GIST following failure of both imatinib and
sunitinib. Nilotinib (Tasigna®, AMN107; Novartis Pharma
AG), a phenylaminopyrimidine, is a selective TKI that may
address this important unmet medical need. Like imatinib,
nilotinib potently inhibits receptor tyrosine kinases KIT and
PDGFR as well as BCR-ABL. Nilotinib has greater in vitro
potency against BCR-ABL than imatinib but exhibits similar
inhibitory activity against KIT and PDGFR kinases [11]. In cell
lines expressing mutant KIT, nilotinib reduces cell viability to
an extent similar to imatinib; it also has potent antiproliferative
activity against imatinib-sensitive forms of KIT and some
activity against certain imatinib-resistant forms of KIT [12].
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Whereas imatinib requires an active transport mechanism via
organic cation transporter-1 for cell entry, nilotinib transport is
mostly passive, which has been shown to result in a 7- to 10-
fold higher intracellular concentration in imatinib-sensitive and
-resistant cell lines, with comparable inhibitory activity to
imatinib [13–16]. This differential cellular uptake is thought to
make nilotinib less susceptible to cellular transport-driven
imatinib resistance [14]. In fact, experimental evidence
indicates that P-glycoprotein, associated with multidrug
resistance, functions to reduce intracellular concentrations of
imatinib in transformed cell lines, conferring drug resistance
[15, 17–19].
Results from clinical studies have shown that nilotinib has
some demonstrable activity in patients with advanced GIST
who are intolerant or resistant to approved TKIs. In a phase I
study of imatinib-resistant/intolerant GIST patients, nilotinib
(400 mg b.i.d.) was well tolerated and demonstrated clinical
activity [20]. Furthermore, retrospective analysis of data from
patients in a compassionate use program with unresectable or
metastatic GIST following failure of all other treatment options
reported that nilotinib treatment resulted in clinical responses
and stable disease (SD) in 10% and 37% of assessable patients,
respectively [21].
The Evaluating Nilotinib Efﬁcacy and Safety in Clinical
Trials (ENEST) g3 study was conducted to assess the potential
clinical beneﬁt of nilotinib in heavily pretreated patients with
advanced GIST and evaluated efﬁcacy and safety of nilotinib
versus best supportive care (BSC) with investigator choice to
include imatinib or sunitinib as part of the BSC regimen in
patients with advanced GIST following failure of both
approved TKIs.
methods
study design
This phase III, randomized, open-label multicenter study was conducted at
50 clinical sites in 13 countries. Between 5 March 2007 and 22 April 2008,
248 patients were randomized 2 : 1 to nilotinib 400 mg b.i.d. (n = 165) or
the control arm (n = 83). Patients in the control arm were treated at
investigator discretion with BSC alone, BSC plus imatinib (BSC + I), or
BSC plus sunitinib (BSC + S). If a TKI was used in BSC, the dose was also
left to the investigator’s discretion; however, higher doses than used
previously were not allowed, and patients in the BSC arm were not
permitted to switch treatments. Patients in the BSC + S group received
sunitinib per the approved regimen of 50 mg/day (4 weeks on/2 week off )
or continuous dosing at 37.5 mg/day. Dose reduction in the study was only
permitted in cases of adverse events (AEs); once reduced, the patient
remained at that reduced dose.
Patients continued treatment until disease progression, unacceptable
toxicity, death, discontinuation for another reason, or until the planned
number of events was reached (to achieve the designed statistical power).
Patients who discontinued the study drug for any reason other than
progression were permitted to have tumor assessments continued during
follow-up.
Following progression assessed by anatomic imaging including
computed tomography (CT) or magnetic resonance imaging (MRI),
patients in the control arm were permitted to cross over to nilotinib. These
patients were considered off the core study but were permitted to enter the
extension study. At the completion of the core study, patients in both arms
who had not progressed were also eligible for entry into the extension
study. All patients were followed up for OS up to 5 years, including those
who discontinued from the study.
patient selection
Eligible patients were aged ≥18 years, with a World Health Organization
(WHO) performance status (PS) of ≤2, and histologically conﬁrmed
unresectable and/or metastatic GIST with either (i) prior progression
(radiologically conﬁrmed by RECIST) on imatinib (≥400 mg/day) and
sunitinib therapy (initiated at 50 mg/day even if progression on a reduced
dose) or (ii) were intolerant to imatinib and/or sunitinib. No limit to the
number of prior therapies was speciﬁed in the study. Treatment with
approved and/or investigational cytotoxic agents was not permitted within
4 weeks (6 weeks for nitrosourea or mitomycin C) before the ﬁrst visit.
Prior treatment with TKIs other than imatinib and sunitinib was not
permitted. Institutional review board approval was obtained at each
participating center, and all patients provided written informed consent.
The overall study design is depicted in Figure 1.
efﬁcacy and safety evaluations
The primary efﬁcacy end point was progression-free survival (PFS) assessed
by central radiology review (CRR). Secondary end points included OS, best
overall response rate, time to tumor response, time to tumor progression,
duration of response, and time to treatment failure. Tumor evaluation (CT
or MRI) was conducted by the local investigator at baseline, day 28, day 56,
and every 56 days thereafter until progression. Each scan was also evaluated
subsequently by blinded CRR per RECIST (v1.0) [22].
AEs were graded according to the National Cancer Institute–Common
Terminology Criteria for Adverse Events v3.0. Safety monitoring included
standard laboratory and cardiac (echocardiogram, electrocardiogram)
assessments. Pharmacokinetic analysis was performed using a sparse
sampling technique for patients randomized to nilotinib. Serum samples
were analyzed using a validated method by liquid chromatography–tandem
mass spectrometry to determine nilotinib concentrations.
Figure 1. Consort diagram. AEs, adverse events; BSC, best supportive
care. Asterisk in the control arm, patients were assigned to the BSC, BSC
plus imatinib, and BSC plus sunitinib groups by the investigator.
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statistical analyses
At an overall, two-sided type I error of 5%, 144 events were needed to
achieve a statistical power of 90% for the primary analysis of PFS using the
log-rank test. Study design hypothesized that median PFS for the nilotinib
and control arms would be 14 and 8 weeks, respectively.
All efﬁcacy data were analyzed for the intent-to-treat (ITT) population
(all randomized patients) at two-sided 0.05 signiﬁcance level using the log-
rank test for time-to-event variables and Fisher’s exact test for response
rates. The hazard ratio (HR) with 95% conﬁdence interval (CI) was
estimated from a Cox regression model. The blinded central reader’s
assessments were used in all analyses except certain sensitivity analyses.
The same analysis methods were used in the post hoc analysis of a
subgroup of patients (true third line) who had exactly one prior regimen
each of imatinib and sunitinib and had well-documented progression or
intolerance to second-line sunitinib [treatment must have stopped within
14 weeks (∼3 months for next assessment) after progression].
All safety data were analyzed for the safety population using descriptive
statistics and/or frequency tables.
results
patient characteristics and disposition
Patient demographics were similar between treatment arms
(Table 1), except for WHO PS grade 0, which were higher in
the nilotinib arm than the control arm (54.5% versus 39.8%,
respectively). At the time of data cut-off (27 June 2008), 74
patients (29.8%) were still on study treatment [58 (35.2%)
nilotinib, 16 (19.3%) control]; the remaining 174 (70.2%) had
discontinued treatment [107 (64.8%) nilotinib, 67 (80.7%)
control]. The most frequently reported reason for treatment
discontinuation in both arms was disease progression [78
(47.3%) nilotinib, 53 (63.9%) control]. AEs were the next most
common reason [18 (10.9%) nilotinib, 6 (7.2%) control]. Sixty-
four patients (77%) crossed over from control to the nilotinib
arm due to disease progression.
The most common primary sites of cancer among
randomized patients were the small intestine (n = 98, 39.5%)
and stomach (n = 83, 33.5%). Most patients were resistant to
imatinib (n = 233, 94.0%) or sunitinib (n = 214, 86.3%); a
minority of patients were intolerant to either medication [15
(6.0%) imatinib, 34 (13.7%) sunitinib; Table 2].
efﬁcacy
All 248 patients were included in the ITT analysis. Based on
the blinded CRR, PFS was not signiﬁcantly different between
the treatment arms [median 109 days nilotinib versus 111 days
control, HR = 0.90, 95% CI (0.65–1.26); P = 0.56] (Figure 2A).
Conversely, according to unblinded local investigator
assessment, PFS was signiﬁcantly longer in the nilotinib arm
Table 1. Patients’ baseline demographics (ITT population)
Demographic variable Nilotinib,
n = 165
Control,
n = 83
Total,
N = 248
Age (years)
n (age range) 165
(18.0–83.0)
83
(37.0–82.0)
248
(18.0–83.0)
Mean age 57.4 58.6 57.8
Sex, n (%)
Male 101 (61.2) 47 (56.6) 148 (59.7)
Female 64 (38.8) 36 (43.4) 100 (40.3)
WHO performance status, n (%)
Grade 0 90 (54.5) 33 (39.8) 123 (49.6)
Grade 1 62 (37.6) 41 (49.4) 103 (41.5)
Grade 2 13 (7.9) 8 (9.6) 21 (8.5)
Missing 0 (0) 1 (1.2) 1 (0.4)
Primary site of cancer, n (%)
Liver 2 (1.2) 1 (1.2) 3 (1.2)
Esophagus 1 (0.6) 0 (0) 1 (0.4)
Stomach 56 (33.9) 27 (32.5) 83 (33.5)
Small intestine 67 (40.6) 31 (37.3) 98 (39.5)
Large intestine 9 (5.5) 5 (6.0) 14 (5.6)
Abdomen 11 (6.7) 11 (13.3) 22 (8.9)
Unknown 6 (3.6) 2 (2.4) 8 (3.2)
Other 13 (7.9) 6 (7.2) 19 (7.7)
Site of metastasis, n (%)
Lung 1 (0.6) 1 (1.2) 2 (0.8)
Liver 93 (56.4) 54 (65.1) 147 (59.3)
Abdomen 30 (18.2) 12 (14.5) 42 (16.9)
Bone 1 (0.6) 0 (0) 1 (0.4)
Other 40 (24.2) 16 (19.3) 56 (22.6)
ITT, intent-to-treat; WHO, World Health Organization.
Table 2. Disease characteristics and history by treatment (ITT population)
Nilotinib,
n = 165
Control,
n = 83
Total,
N = 248
Prior experience with imatinib, n (%)
Imatinib resistant 156 (94.5) 77 (92.8) 233 (94.0)
Imatinib intolerant 9 (5.5) 6 (7.2) 15 (6.0)
Time on imatinib (months)
<6 15 (9.1) 5 (6.0) 20 (8.1)
6 to <12 14 (8.5) 9 (10.8) 23 (9.3)
12 to <24 37 (22.4) 24 (28.9) 61 (24.6)
24 to <36 37 (22.4) 19 (22.9) 56 (22.6)
36 to <48 35 (21.2) 12 (14.5) 47 (19.0)
48 to <60 16 (9.7) 9 (10.8) 25 (10.1)
≥60 11 (6.7) 5 (6.0) 16 (6.5)
Prior experience with sunitinib, n (%)
Sunitinib resistant 146 (88.5) 68 (81.9) 214 (86.3)
Sunitinib intolerant 19 (11.5) 15 (18.1) 34 (13.7)
Time on sunitinib (months)
<6 55 (33.3) 26 (31.3) 81 (32.7)
6 to <12 45 (27.3) 20 (24.1) 65 (26.2)
12 to <18 34 (20.6) 17 (20.5) 51 (20.6)
18 to <24 17 (10.3) 12 (14.5) 29 (11.7)
≥24 14 (8.5) 8 (9.6) 22 (8.9)
Time since diagnosis of primary site to study randomization (months)
n 165 83 248
Mean (range) 63.6
(10.4–373.9)
62.3
(12.4–384.2)
63.1
(10.4–384.2)
Time since last relapse on imatinib and/or sunitinib to study
randomization (months)
n 165 80 245
Mean (range) 2.9 (0.2–25.0) 4.8 (0.1–41.1) 3.5 (0.1–41.1)
ITT, intent-to-treat.
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compared with the control arm [median 119 versus 70 days,
respectively, HR 0.58, 95% CI (0.42–0.80); log-rank test P =
0.0007] (Figure 2B). High discordance was observed between
the evaluations of PFS made by local assessment versus central
review. The overall discordance rate was 25.4% for PFS status
(event or censoring) and 47.6% for time to event (48.5%
nilotinib, 45.8% control). In addition, the two independent
blinded central readers displayed a high discordance rate when
reading scans from the same subject, requiring the involvement
of an adjudicator in 48.4% of cases.
Based on blinded CRR, one patient had a partial response
(PR) in the nilotinib arm, and no patients achieved a complete
response (CR) in either arm (supplemental Table A1, available
at Annals of Oncology online). The overall clinical beneﬁt rate
(CBR = CR/PR/SD) in the nilotinib arm was 52.7% versus
44.6% in the control arm (P = 0.28). A CBR lasting >6 months
was observed in 12 patients (7.3%) in the nilotinib arm and 1
patient (1.2%) in the control arm; this difference was not
statistically signiﬁcant (P = 0.065).
Although the study was not powered to detect statistically
signiﬁcant differences in OS in the ITT population, a
nonstatistically signiﬁcant trend in favor of the nilotinib arm
was observed [median 332 versus 280 days; HR = 0.79, 95% CI
(0.52–1.22); P = 0.29] (supplemental Figure 1A, available at
Annals of Oncology online); this difference is particularly
notable because 64 patients (77%) crossed over from the
control arm to the nilotinib arm following progression;
crossover usually occurred rapidly on control (median duration
70 days on control arm).
pharmacokinetics
The average minimum concentration (Cmin) of nilotinib was
1037 ± 660 ng/ml, similar to previous ﬁndings [23]. Steady-
state nilotinib concentrations were found to remain stable over
the treatment course.
exploratory post hoc analyses
Recognizing that 41 patients (16.5%) in the ITT population
had undergone treatment with more than two prior agents and
10 patients (4%) were accrued to the trial without well-
documented progression on second-line treatment, an
exploratory post hoc analysis was conducted to evaluate the
true effect of nilotinib in a well-deﬁned third-line patient
population (true third line). This population (n = 197, 79.4% of
total ITT) included all patients who had documented
progression (or intolerance) after exactly one prior regimen
each of imatinib and sunitinib. Progression on sunitinib was
determined by RECIST within 14 weeks (∼3 months for next
assessment) of ceasing sunitinib. Based on the last survival
follow-up (data cut-off 28 August 2009), patients in this
subpopulation had a signiﬁcantly longer OS on the nilotinib
arm (n = 132) than those in the control arm [n = 65; median
OS 405 versus 280 days, HR = 0.67, 95% CI (0.48, 0.95); P =
0.02] (Figure 3), a difference not observed in the ITT
population using the same data cut-off [median 361 versus 300
days; HR = 0.84, 95% CI (0.62, 1.15); P = 0.28].
safety and tolerability
Median dose intensity was 800 mg/day for nilotinib, 669.5 mg/
day for imatinib (BSC + I), and 33.3 mg/day for sunitinib
(BSC + S). The median duration of exposure to treatment
(including periods of temporary study drug interruption) was
113 days for the nilotinib arm and 70 days for the control arm
(50 days BSC, 57.5 days BSC + I, 141 days BSC + S). Dose
reduction was reported in 19 patients (7.7%) overall, including
15 (9.1%) in the nilotinib arm and 4 (4.8%) in the control arm
(2 patients each in the BSC + I and BSC + S groups). Treatment
interruption was reported in 68 patients (27.4%), including 49
(29.7%) in the nilotinib arm and 19 (22.9%) in the control arm
[13 patients (24.1%) in the BSC + I group and 6 patients
(26.1%) in the BSC + S group].
AEs were reported in 242 patients (97.6%); most AEs were
gastrointestinal in origin. The most frequently reported AEs for
nilotinib were abdominal pain (35.2%), nausea (29.7%), fatigue
(26.7%), asthenia (25.5%), anorexia (23.6%), and anemia
(21.2%) (Table 3).
Grade 3/4 drug-related AEs were reported in 39 patients
(15.7%; Table 4). In the nilotinib arm, the most common grade
3/4 AEs were asthenia (3%), increased lipase (1.8%), abdominal
Figure 2. PFS based on central (A) and local (B) radiological review (intent-to-treat population). Data cut-off 27 June 2008. PFS, progression-free survival.
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Figure 3. Overall survival in the intent-to-treat population (A) and the ‘true third-line’ only patient population (B). Data cut-off 28 August 2009. CI,
conﬁdence interval; HR, hazard ratio.
Table 3. Adverse events reported in at least 10% of patients (safety population)
Adverse event, n (%) Nilotinib, n = 165 Control BSC + I, n = 54 Control BSC + S, n = 23 Control BSC, n = 6 Control total, n = 83 Total, N = 248
Any event 164 (99.4) 52 (96.3) 21 (91.3) 5 (83.3) 78 (94.0) 242 (97.6)
Nausea 49 (29.7) 29 (53.7) 3 (13.0) 0 (0) 32 (38.6) 81 (32.7)
Abdominal pain 58 (35.2) 13 (24.1) 6 (26.1) 3 (50.0) 22 (26.5) 80 (32.3)
Fatigue 44 (26.7) 10 (18.5) 4 (17.4) 1 (16.7) 15 (18.1) 59 (23.8)
Vomiting 33 (20.0) 22 (40.7) 3 (13.0) 0 (0) 25 (30.1) 58 (23.4)
Anorexia 39 (23.6) 15 (27.8) 0 (0) 2 (33.3) 17 (20.5) 56 (22.6)
Anemia 35 (21.2) 20 (37.0) 0 (0) 0 (0) 20 (24.1) 55 (22.2)
Peripheral edema 28 (17.0) 23 (42.6) 2 (8.7) 0 (0) 25 (30.1) 53 (21.4)
Asthenia 42 (25.5) 6 (11.1) 1 (4.3) 1 (16.7) 8 (9.6) 50 (20.2)
Constipation 34 (20.6) 6 (11.1) 0 (0) 1 (16.7) 7 (8.4) 41 (16.5)
Diarrhea 22 (13.3) 12 (22.2) 7 (30.4) 0 (0) 19 (22.9) 41 (16.5)
Headache 32 (19.4) 3 (5.6) 4 (17.4) 0 (0) 7 (8.4) 39 (15.7)
Pyrexia 28 (17.0) 6 (11.1) 2 (8.7) 0 (0) 8 (9.6) 36 (14.5)
Dyspnea 21 (12.7) 10 (18.5) 2 (8.7) 0 (0) 12 (14.5) 33 (13.3)
Rash 26 (15.8) 4 (7.4) 3 (13.0) 0 (0) 7 (8.4) 33 (13.3)
Back pain 25 (15.2) 4 (7.4) 0 (0) 1 (16.7) 5 (6.0) 30 (12.1)
Weight decreased 24 (14.5) 3 (5.6) 0 (0) 1 (16.7) 4 (4.8) 28 (11.3)
Upper abdominal pain 18 (10.9) 6 (11.1) 1 (4.3) 1 (16.7) 8 (9.6) 26 (10.5)
Cough 17 (10.3) 5 (9.3) 1 (4.3) 0 (0) 6 (7.2) 23 (9.3)
Myalgia 18 (10.9) 2 (3.7) 1 (4.3) 0 (0) 3 (3.6) 21 (8.5)
Pruritus 19 (11.5) 2 (3.7) 0 (0) 0 (0) 2 (2.4) 21 (8.5)
BSC, best supportive care; BSC + I, BSC plus imatinib; BSC + S, BSC plus sunitinib.
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pain, increased alanine aminotransferase, anorexia, headache,
anemia, vomiting, and myalgia (1.2% each). Grade 3/4 anemia
(1.2% versus 4.8%) and neutropenia (0% versus 2.4%) were less
frequent in the nilotinib arm compared with control. All cases
of grade 3/4 neutropenia were reported in the BSC + S (8.7%)
group of the control arm. Serious AEs (SAEs; grade 3/4) were
reported in a total of 80 patients (32.3%), comprising 58
patients (35.2%) in the nilotinib arm and 22 (26.5%) in the
control arm. The most common grade 3/4 SAEs involved the
gastrointestinal tract (14.5%; 15.2% nilotinib, 13.3% control).
A total of 21 deaths were reported within 28 days after the
last dose of study drug during the study period. Fourteen
deaths (8.5%) occurred in the nilotinib arm and seven (8.4%)
in the control arm [one patient (16.7%) in the BSC group and
six patients (11.1%) in the BSC + I group].
discussion
This phase III study investigating the efﬁcacy and safety of
nilotinib versus BSC in patients with unresectable or metastatic
GIST who progressed on or were intolerant of imatinib and
sunitinib did not meet the primary end point according to
CRR. However, for the same end point as assessed by local
investigators, nilotinib provided a signiﬁcant lengthening of
median PFS compared with control.
The overall discordance rate between local and central
reviews was 25.4% in PFS event status and 47.6% in time to
event. In addition, high adjudication rates (48.4%) between
central reviewers were observed, documenting the difﬁculty
associated with use of RECIST in heavily treated patients who
often have bulky and multifocal drug-resistant GIST. A
signiﬁcantly higher rate of nontarget lesions at baseline was
identiﬁed by central review (91%) compared with local review
(63%), and central reviewers determined disease progression
much more frequently based solely on worsening of nontarget
lesions (31 cases, 20.1% of all progression) than local
reviewers (9 cases, 6.3% of all progression). Additional,
exploratory, blinded radiological analyses were conducted, but
high discordance between the two groups of reviewers was
still observed. The discordance between blinded CRR and
local investigator review in this population of patients with
advanced GIST suggests that it may be difﬁcult to assess
efﬁcacy by an imaging method alone, without taking into
account clinical details to inform the status of disease in the
patient.
There are several potential reasons for this discrepancy
between local and central evaluations of PFS. As this was an
open-label trial, investigator bias may be a factor; local
investigators may also have had access to more robust patient
information and clinical data to inform their clinical
assessments. Advanced GIST also can be complex to assess by
RECIST because of reported cases of ‘false progressions’ (i.e.
volumetric progression despite clinical improvements and with
metastases that can increase in size due to necrotic changes
and perhaps intratumoral bleeding) [24, 25]. In fact, in the
EORTC 62005 study, subjective progression (per the
investigator) was associated with worse prognosis than
progression deﬁned by volumetric increase by RECIST
alone [26].
The use of RECIST to evaluate PFS may be another
explanation for the discrepancy in evaluations, as RECIST can
underestimate the true rates of beneﬁcial treatment response to
molecularly targeted therapy, especially in GIST [27]. Size-based
criteria included in RECIST were originally designed to measure
responses to cytotoxic agents, and the limitations of these criteria
have been extensively discussed [24, 28, 29]. Moreover,
determining the types of changes that are indicative of a true
response following TKI therapy can also be problematic. TKI-
responsive GIST may initially increase in size but simultaneously
become cystic, complicating the interpretation of whether a
patient’s tumor was truly progressing [27]. In this trial, the use of
RECIST might have obscured the interpretation of results in
certain patients by incorrectly declaring them as having
progressive disease [24, 25].
Table 4. Grade 3 or 4 drug-related adverse events reported in at least 1% of patients (safety population)
Adverse event, n (%) Nilotinib, n = 165 Control BSC + I, n = 54 Control BSC + S, n = 23 Control total, n = 83 Total, N = 248
Any event 29 (17.6) 5 (9.3) 5 (21.7) 10 (12.0) 39 (15.7)
Anemia 2 (1.2) 4 (7.4) 0 (0) 4 (4.8) 6 (2.4)
Asthenia 5 (3.0) 0 (0) 0 (0) 0 (0) 5 (2.0)
Increased lipase 3 (1.8) 0 (0) 0 (0) 0 (0) 3 (1.2)
Abdominal pain 2 (1.2) 0 (0) 0 (0) 0 (0) 2 (0.8)
Increased alanine aminotransferase 2 (1.2) 0 (0) 0 (0) 0 (0) 2 (0.8)
Anorexia 2 (1.2) 0 (0) 0 (0) 0 (0) 2 (0.8)
Diarrhea 1 (0.6) 0 (0) 1 (4.3) 1 (1.2) 2 (0.8)
Fatigue 1 (0.6) 0 (0) 1 (4.3) 1 (1.2) 2 (0.8)
Headache 2 (1.2) 0 (0) 0 (0) 0 (0) 2 (0.8)
Myalgia 2 (1.2) 0 (0) 0 (0) 0 (0) 2 (0.8)
Neutropenia 0 (0) 0 (0) 2 (8.7) 2 (2.4) 2 (0.8)
Vomiting 2 (1.2) 0 (0) 0 (0) 0 (0) 2 (0.8)
Gastrointestinal hemorrhage 0 (0) 1 (1.9) 0 (0) 1 (1.2) 1 (0.4)
Septic shock 0 (0) 1 (1.9) 0 (0) 1 (1.2) 1 (0.4)
Thrombocytopenia 0 (0) 0 (0) 1 (4.3) 1 (1.2) 1 (0.4)
BSC + I, best supportive care plus imatinib; BSC + S, best supportive care plus sunitinib.
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Despite a high proportion of crossover from the control arm
to the nilotinib arm, OS was nearly 2 months longer in the
nilotinib arm compared with control. This trend was not
statistically signiﬁcant, partly given that this study was not
powered to detect statistically signiﬁcant differences in OS in
the ITT population.
Given that 51 patients [21%; 33 (20%) nilotinib, 18 (22%)
control] in the ITT population had undergone treatment with
more than two prior regimens or were accrued to the trial
without well-documented progression on prior sunitinib, a post
hoc analysis was conducted to evaluate OS with longer follow-
up in a ‘true third-line’ patient population. In this population, a
signiﬁcantly longer median OS of >4 months was observed in
patients in the nilotinib arm compared with control. These
ﬁndings suggest that true third-line patients with advanced
GIST experienced a substantial clinical beneﬁt following
nilotinib treatment. In fact, in the later stages of GIST, OS may
be a more objective end point, due to the limitations of RECIST
in interpreting progression in patients with this disease.
In summary, although the study failed to meet its primary
end point based on CRR, nilotinib was associated with a
nonstatistically signiﬁcant improvement in median OS in the
ITT population, which is more clearly demonstrated in the
signiﬁcantly longer median OS (>4 months) in an exploratory
post hoc analysis of a well-deﬁned population of true third-line
patients. Nilotinib was well tolerated; most AEs were
manageable, nonhematologic, similar in frequency between
treatment arms, and consistent with those reported in other
clinical studies [30]. Based on its activity in this heterogeneous
and extensively pretreated patient population, further
evaluation of nilotinib in a well-deﬁned population of patients
with GIST is warranted. Other studies have been initiated in
patients with advanced GIST, in the ﬁrst-line setting, including
a ﬁrst-line pilot study and ENEST g1, a phase III open-label
study of nilotinib versus imatinib as ﬁrst-line therapy for
advanced GIST [31, 32].
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Serial FDG–PET/CT for early outcome prediction in
patients with metastatic colorectal cancer undergoing
chemotherapy
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Background: The study purpose was to assess the predictive value of 2-[ﬂuorine-18]ﬂuoro-2-deoxy-D-glucose
(FDG)–positron emission tomography (PET)/computerized tomography (CT) metabolic response after a single course of
chemotherapy in patients with metastatic colorectal cancer (mCRC).
Patients and methods: FDG–PET/CT scans were carried out at baseline and on day 14 in 41 patients with
unresectable mCRC treated with a biweekly regimen of chemotherapy. Metabolic nonresponse was deﬁned by <15%
decrease in FDG uptake in the dominant proportion of the patient’s lesions or if a lesion was found metabolically
progressive. The PET-based response was correlated with radiological response (primary end point) and patient’s
outcome (secondary end points).
Results: RECIST response rate in metabolically responding patients was 43% (10 of 23) compared with 0% (0 of 17)
in nonresponding patients (P = 0.002). The metabolic assessment’s predictive performance for RECIST response was
sensitivity 100% [95% conﬁdence interval (CI) 69% to 100%], speciﬁcity 57% (95% CI 37% to 75%), positive predictive
value 43% (95% CI 23% to 66%), and negative predictive value 100% (95% CI 80% to 100%). Comparing
metabolically responding versus nonresponding patients, the hazard ratio (HR) was 0.28 (95% CI 0.10–0.76) for overall
survival and 0.57 (95% CI 0.27–1.21) for progression-free survival.
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